Alignment Healthcare (NASDAQ:ALHC) Insider Christopher Joyce Sells 25,125 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Christopher Joyce sold 25,125 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $17.84, for a total transaction of $448,230.00. Following the completion of the transaction, the insider owned 323,464 shares of the company’s stock, valued at approximately $5,770,597.76. This trade represents a 7.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alignment Healthcare Stock Down 0.2%

Shares of NASDAQ ALHC opened at $18.16 on Friday. Alignment Healthcare, Inc. has a 12-month low of $11.63 and a 12-month high of $23.87. The stock has a market cap of $3.71 billion, a P/E ratio of -1,814.19, a PEG ratio of 2.66 and a beta of 1.18. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. The business’s fifty day simple moving average is $20.51 and its 200-day simple moving average is $18.78.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.Alignment Healthcare’s revenue was up 44.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.16) EPS. As a group, equities analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ALHC. TD Cowen lifted their price target on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. KeyCorp restated an “overweight” rating and issued a $28.00 price objective on shares of Alignment Healthcare in a report on Thursday, January 22nd. Piper Sandler lifted their price objective on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Wall Street Zen downgraded shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.56.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Analyst optimism — several brokerages have raised price targets and maintained Overweight/Buy views (Piper Sandler, KeyCorp, JPMorgan, Robert W. Baird), supporting upside expectations and a consensus “Moderate Buy” rating. MarketBeat ALHC Analyst Coverage
• Positive Sentiment: Recent earnings beat — Alignment reported Q4 revenue of ~$1.01B and EPS of ($0.05), topping consensus (revenue ~ $1.00B; EPS -$0.15), showing strong revenue growth (Y/Y +44%). This fundamental print remains supportive. Earnings Summary
• Neutral Sentiment: Zacks comparison piece — a valuation/comparison article contrasts ALHC with BrightSpring (BTSG); useful context for long-term investors but not an immediate market catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Reported short-interest data appears erroneous (shows 0 shares / NaN changes). Do not treat published short-interest figures as evidence of rising short pressure until exchanges correct the data.
• Negative Sentiment: CEO sale — John E. Kao sold 73,046 shares at an average $17.84 (~$1.30M), trimming his stake ~3.93%. This large insider sale is a near-term negative signal for sentiment. SEC Filing — Kao
• Negative Sentiment: Multiple senior insider sales on Mar 18 — President Dawn C. Maroney (36,749 shares, $17.84; also several prior sales in March/Jan), COO Sebastian Burzacchi (15,361 shares, $17.84), Christopher J. Joyce (25,125 shares, $17.84), Hyong Kim (18,404 shares, $17.84), Andreas P. Wagner (12,000 @ $17.84 and 11,602 @ $18.22), and Robert L. Scavo (11,285 shares, $17.84). These clustered disposals by senior management create headline risk and downward pressure. Representative filings: Maroney — Maroney SEC Filing; Joyce — Joyce SEC Filing; Wagner filings — Wagner SEC Filing

Institutional Investors Weigh In On Alignment Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP increased its position in Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after buying an additional 6,940,277 shares during the period. Invesco Ltd. grew its position in shares of Alignment Healthcare by 122.3% during the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after acquiring an additional 2,294,739 shares during the last quarter. Capital World Investors acquired a new position in shares of Alignment Healthcare in the 4th quarter valued at $44,203,000. Loomis Sayles & Co. L P acquired a new position in shares of Alignment Healthcare in the 4th quarter valued at $44,162,000. Finally, Danica Pension Livsforsikringsaktieselskab purchased a new stake in Alignment Healthcare in the 4th quarter valued at $39,500,000. 86.19% of the stock is currently owned by institutional investors and hedge funds.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.